Abstract Number: 2345 • 2015 ACR/ARHP Annual Meeting
Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study
Background/Purpose: Patients with gouty arthritis (GA) experience frequent flares with pain and inflammation. The limited available treatment options and typical comorbidities warrant effective alternative treatments1.…Abstract Number: 2350 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Febuxostat in 55 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Results from a Retrospective Multicenter Study
Background/Purpose: Although allopurinol is the first urate lowering therapy (ULT), its limited dosage in gouty patients with stage 4 or 5 chronic kidney disease (CKD…Abstract Number: 2351 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) for the treatment of gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular…Abstract Number: 2352 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study
Background/Purpose: In the randomized, double-blind, placebo-controlled, Phase III CRYSTAL trial, more patients taking lesinurad 200 mg (LESU200) or 400 mg (LESU400), in combination with febuxostat…Abstract Number: 2354 • 2015 ACR/ARHP Annual Meeting
The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Background/Purpose: Previous studies have shown that long-term urate-lowering therapy (ULT) is required for improvements in gout flare frequency and tophi reduction, and that lower serum…Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…Abstract Number: 2465 • 2015 ACR/ARHP Annual Meeting
Cytokine Profile Comparison of Monogenic and Complex Conditions with Interferon-Regulated Gene Signatures in Chronic Atypical Neutrophilic Dermatosis with Lipodsytrophy and Elevated Temperature (CANDLE), SAVI, Aicardi-Goutieres Syndrome, JDM, and SLE
Background/Purpose: An Interferon (IFN) Regulated Gene Signature (IRS) was previously reported in patients with two complex autoimmune diseases, juvenile systemic lupus (JSLE)1 and juvenile dermatomyositis…Abstract Number: 3078 • 2015 ACR/ARHP Annual Meeting
ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout
Background/Purpose: Many patients fail to reach target serum urate (SU) on allopurinol. Although the most common causes of inadequate response are non-adherence and low dosing…Abstract Number: 3165 • 2015 ACR/ARHP Annual Meeting
Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Attacks?
Background/Purpose: Current guidelines for gout management, based in part on epidemiologic data for development of incident gout, recommend limiting intake of high-purine fish. However,…Abstract Number: 3166 • 2015 ACR/ARHP Annual Meeting
Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout
Background/Purpose: The acute gout flare results from a localised self-limiting innate immune response to monosodium urate (MSU) crystals deposited in joints in hyperuricaemic individuals. Activation…Abstract Number: 3167 • 2015 ACR/ARHP Annual Meeting
Association of the Apolipoprotein A1-C3-A4 Gene Cluster with the Risk of Gout: Evidence for a Causal Role in Gout
Background/Purpose: Gout is caused by an inflammatory response to monosodium urate (MSU) crystals and is associated with elevated triglyceride and very low density lipoprotein levels.…Abstract Number: 3168 • 2015 ACR/ARHP Annual Meeting
How Strong Cardiovascular Risk Factor Are Gouty Tophi?
Background/Purpose: We have not found a study determining cardiovascular (CV) risk in the different stages of gout. This led us to use a complex multimodal…Abstract Number: 3169 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study
Background/Purpose: Musculoskeletal ultrasound (US) is a non-invasive option for diagnosing gout. However, little is known about the test characteristics of US for the diagnosis of…Abstract Number: 2958 • 2014 ACR/ARHP Annual Meeting
Polygenic Analysis of Transport, Metabolism and Immune Related Genomic Compartments in Serum Urate and Gout
Background/Purpose: Genome wide association studies (GWAS) have identified loci associated with complex traits, and the current challenge is to glean biological insights from these findings.…Abstract Number: 2959 • 2014 ACR/ARHP Annual Meeting
Twenty-Eight Loci That Influence Serum Urate Levels: Analysis of Association with Gout
Background/Purpose: Twenty-eight genetic loci are associated with serum urate levels in Europeans. Ten are established, with a further 18 of weaker effect more recently detected.…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »